The Promise of EZH2 Inhibitors in Rare and Aggressive Cancers
A potential family of medications known as EZH2 inhibitors is made to specifically target and alter the activity of EZH2, a crucial protein involved in the regulation of genes and other biological processes. Enhancer of Zeste Homolog 2, or EZH2, is a part of the polycomb repressive complex 2 (PRC2), which is essential for preserving cellular identity and gene silence. Since this protein is...
0 Comments
0 Shares